REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

CQGE031C2302E1 Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

13/08/2025 19:28:57 Main Information Primary registry identifying number Protocol number LBCTR2020094573 CQGE031C2302E1 MOH registration number Study registered at the country of origin Study registered at the country of origin: Specify Yes Type of registration Type of registration: Justify Prospective N/A Date of registration in national regulatory agency **Primary sponsor** Primary sponsor: Country of origin Novartis Pharmaceuticals **Novartis Pharmaceuticals** Date of registration in primary registry Date of registration in national regulatory agency 15/09/2020 Public title Acronym CQGE031C2302E1 Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab Scientific title Acronym A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 Brief summary of the study: English The purpose of this extension study is to establish efficacy and safety of ligelizumab. This will be assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who have completed a preceding ligelizumab study and have relapsed, following treatment in these preceding studies, despite standard of care H1antihistamine (H1-AH) treatment. In a subset of subjects, the safety and efficacy of ligelizumab monotherapy will be assessed. This study will also fulfill the Novartis commitment to provide posttrial access to patients who have completed studies CQGE031C2302, CGQE031C2303, CQGE031C2202 or CQGE031C1301 Brief summary of the study: Arabic

در اسة تمديد متعدّدة المراكز ومزدوجة التعمية ومفتوحة اللصاقة لتقييم فعاليّة وسلامة ليجيليزوماب كإعادة معالجة وعلاج يُعطى ذاتيًا ومعالجة أو CQGE031C2302، CQGE031C2303، CQGE031C2202 أحاديّة لدى مرضى الشرى التلقاني المزمن الذين أنجزوا دراسات CQGE031C1301 REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Health conditions/problem studied: Specify

Chronic Spontaneous Urticaria

Interventions: Specify Drug: Ligelizumab liquid in vial 120 mg/mL Prefilled Syringe 120 mg/mL Other Name: QGE031 Key inclusion and exclusion criteria: Inclusion criteria Key Inclusion Criteria: Written informed consent •Subjects who successfully completed all of the treatment period and the follow-up period in any of the following studies: CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 •Male and female, adult and adolescent subjects ≥12 years of age •Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedule Key inclusion and exclusion criteria: Gender Key inclusion and exclusion criteria: Specify gender Both Key inclusion and exclusion criteria: Age minimum Key inclusion and exclusion criteria: Age maximum 12 99 Key inclusion and exclusion criteria: Exclusion criteria Key Exclusion Criteria: •Use of investigational drugs, other than those in use in the preceding studies, at the time of enrollment ·Use of omalizumab within 16 weeks of Screening •History of hypersensitivity to the study drug ligelizumab or its components, or to drugs of similar chemical classes •New onset or signs and symptoms of any form of chronic urticarias other than CSU during the preceding studies CQGE031C2302, CQGE031C2303 or CQGE031C2202. •Diseases with possible symptoms of urticaria or angioedema ·Subjects with evidence of helminthic parasitic infection •Documented history of anaphylaxis Pregnant or nursing (lactating) women Type of study Interventional Type of intervention Type of intervention: Specify type Pharmaceutical N/A **Trial scope** Trial scope: Specify scope Therapy N/A Study design: Allocation Study design: Masking Non-randomized controlled trial Blinded (masking used) Study design: Control Study phase N/A 3 Study design: Purpose Study design: Specify purpose Treatment N/A Study design: Assignment Study design: Specify assignment Parallel N/A IMP has market authorization IMP has market authorization: Specify No Name of IMP Year of authorization Month of authorization

Ligelizumab



Lebanon Clinical Trials Registry

Гуре of IMP	
mmunological	
Pharmaceutical class	
igelizumab is a high-affinity anti-human-IgE	
Therapeutic indication	
Patients with: Chronic Spontaneous Urticaria	
Therapeutic benefit	
improvement of CSU symptoms including itch, hives, angioedema	
Study model	Study model: Explain model
N/A	N/A
Study model: Specify model	
N/A	
Time perspective	Time perspective: Explain time perspective
N/A	N/A
Fime perspective: Specify perspective	
N/A	
Farget follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention	Biospecimen description
Samples without DNA	Samples will be sent to Q2 central Lab for analysis
Target sample size	Actual enrollment target size
10	
Date of first enrollment: Type	Date of first enrollment: Date
Anticipated	30/09/2020
Date of study closure: Type	Date of study closure: Date
Anticipated	16/12/2026
Recruitment status	Recruitment status: Specify
Pending	·····
-	
Date of completion	
20/04/2022	



Lebanon Clinical Trials Registry

IPD sharing statement plan

No

IPD sharing statement description

Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Additional data URL

https://clinicaltrials.gov/ct2/show/record/NCT04210843?cond=ligelizumab&draw=3

Admin comments

Trial status

Approved

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
Clinical trials.gov	NCT04210843	

Sources of Monetary or Material Support Name Novartis Pharma services

Secondary Sponsors Name NA

Contac	Contact for Public/Scientific Queries					
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Hadi Hamam	Saida	Lebanon	+961 3 795 246	hadihamam@hot mail.com	Hammoud Hospital
Scientific	Hind Khairallah	Sin El Fil	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l.






Centers/Hospitals Involved in the Study			
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hammoud Hospital University Medical Center	Dr Hadi Hamam	Dermatology	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hammoud Hospital University Medical Center	28/05/2020	Ahmad Zaatari	zaatari@hammoudhospital.com	961 (0) 7 723111 ext 1160

Countries of Recruitment
Name
Australia
Austria
Belgium
Canada
Czech Republic
France
Germany
Greece
Hungary
Japan
Republic of Korea
Slovakia
Spain
Thailand
Lebanon





Health Conditions or Problems Studied		
Condition	Code	Keyword
chronic spontaneous urticaria	Urticaria, unspecified (L50.9)	chronic spontaneous urticaria

Interventions		
Intervention	Description	Keyword
Informed consent, questionnaires, Lab tests drug administration	s, Informed consent, questionnaires, Lab tests, drug administration	ICF, Lab, ECG, IMP

Primary Outcomes			
Name	Time Points	Measure	
proportion of subjects with well-controlled disease USA7	Week 12	Week 12	
Reduction in number of hives and itch	week 12	week 12	
Improvement of severity of itch	week 12	week 12	

Key Secondary Outcomes		
Name	Time Points	Measure
Complete control of chronic spontaneous urticaria (CSU)	week 12	week 12
Reduction from extension baseline in weekly itch severity score (ISS7)	ISS over the preceding 7 days	ISS over the preceding 7 days
Reduction from extension baseline in weekly Urticaria Activity Score (UAS7)	week 12	week 12
Reduction from extension baseline in weekly hives severity score HSS7	week 12	week 12
Achieving a weekly angioedema-free period (AAS7) = 0	week 12	week 12
Percentage of subjects achieving Dermatology Life Quality Index (DLQI) = 0-1	week 12	week 12
Efficacy of ligelizumab in the treatment of CSU after self administration	week 12	week 12
Safety and tolerability of ligelizumab 120 mg q4w after self administration	week 12	week 12



Trial Results Summary results Study results globally Date of posting of results summaries Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files